Stock Analysis
Novo Nordisk A/S (NVO) Stock Analysis
Novo Nordisk A/S (NVO) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Novo Nordisk A/S (NVO) currently has an AIQ Score of 67/100, indicating a neutral setup. Quality is the strongest factor at 91/100. Risk is the weakest current factor at 51/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
NVO at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $39.06 |
| AIQ Score | 67/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Neutral |
| Market Cap | $200.36B |
| P/E Ratio (TTM) | 11.21 |
| Forward P/E | — |
| EPS (quarter ended 2026-06-30) | $4.74 |
| Revenue (quarter ended 2026-06-30) | $78.49B |
| Dividend Yield (TTM) | 2.55% |
| Beta | 0.35 |
| Volume | 6.81M |
| 52-week range | $35.12-$64.16 |
| RSI 14 | 65.54 |
| 50-Day SMA | $42.20 |
| 200-Day SMA | $44.86 |
| Analyst Price Target | $43.50 |
| Next Earnings | Nov 4, 2026 |
NVONovo Nordisk A/S
Healthcare / Drug Manufacturers - General
Leader
Strong Relative Position
Latest quote
- Momentum56
- Value60
- Quality91
- Risk resilience51
- Sentiment—
NVO Stock Analysis Summary
Novo Nordisk A/S (NVO) currently has an AIQ Score of 67/100, indicating a neutral setup. Quality is the strongest factor at 91/100. Risk resilience is the weakest current factor at 51/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, NVO has AIQ Score of 67/100 with Quality base of 91/100 and fading Risk resilience at 51/100. Wait for component alignment before adding exposure.
Quality (91/100) leads while Risk resilience (51/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -0.74% stock move · NVO classified in Drug Manufacturers - General.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is NVO Bullish or Bearish Right Now?
NVO currently has a neutral overall setup. Quality is the strongest factor at 91/100, while Risk Resilience is weakest at 51/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Quality is supportive at 91/100.
- - Analyst target implies +11.37% upside from the latest quote.
- - Price is -12.93% below its 200-day SMA.
- - Technical consensus has more sell votes than buy votes (20 vs 19).
Current Consensus
NVO's Technical Analysis Consensus is currently Neutral, with 19 buy, 6 neutral, and 20 sell votes. NVO's 14-day RSI is 65.54, which places the stock in a constructive momentum range. NVO's beta is 0.35, indicating lower market sensitivity than the broad market.
What Changed in NVO?
The largest recent change in NVO is Momentum moving up by 19.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.
What Would Change the NVO Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
NVO Decision Framework
Public evidence layers, setup checks, and risk context for Novo Nordisk A/S.
Novo Nordisk A/S (NVO) Stock Analysis
Novo Nordisk A/S has an AIQ Score of 67/100 in a Neutral regime. Quality is strongest at 91/100. Beta is 0.35, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | NVO is in a Neutral AIQ regime with score 67/100. |
| Signal Conflict | The primary conflict is that quality leads at 91/100 while risk lags at 51/100. |
| Factor Evidence | Momentum 56/100 · Value 60/100 · Quality 91/100 · Risk 51/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Quality is the strongest factor at 91/100.
Momentum is 56/100 and RSI (14) is 65.5.
NVO is in a Neutral regime at 67/100.
Risk factor is 51/100 with beta 0.35 and annual volatility 45.71%.
Current conflict: quality leads at 91/100 while risk lags at 51/100.
NVO Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
NVO Fundamentals
NVO valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
NVO Technical Analysis
NVO technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
NVO Stock Catalysts
Track NVO earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
NVO Dividend Analysis
NVO dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
NVO Financial Data
NVO revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
NVO Risk Analysis
NVO volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
NVO Stock News
NVO stock news, market tone, recent headlines, and catalyst context.
NVO vs Large-Cap Pharma Peers
Current peer cohort: NVO · LLY · PFE · MRK · ABBV. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| NVO Current stock | 67/100 | 60/100 | 56/100 | 51/100 | -0.63 | 45.71% | Current |
| LLY Eli Lilly | 62/100 | 26/100 | 95/100 | 50/100 | 1.36 | 34.89% | NVO vs LLY |
| PFE Pfizer | 64/100 | 67/100 | 79/100 | 54/100 | 0.81 | 21.51% | NVO vs PFE |
| MRK Merck | 47/100 | 27/100 | 71/100 | 44/100 | 1.88 | 29.63% | NVO vs MRK |
| ABBV AbbVie | 56/100 | 36/100 | 82/100 | 44/100 | 0.77 | 25.89% | NVO vs ABBV |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Oct 21, 2026.
Popular NVO Comparisons
How NVO scores against the names it is most often compared with.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts3 recent quarterly periods are available for review.
Checked Oct 21, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching NVO
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for NVO
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
NVO Stock FAQ
What is NVO stock price today?
Novo Nordisk A/S's current stock price is $39.06. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is NVO bullish or bearish right now?
NVO's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is NVO's market cap?
NVO's market cap is $200.36B based on the latest completed market-close snapshot from Oct 21, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is NVO's current P/E ratio?
NVO's current P/E ratio is 11.21 based on the latest completed market-close snapshot from Oct 21, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is NVO's RSI?
NVO's 14-day RSI is 65.54 based on the latest completed market-close snapshot from Oct 21, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is NVO above its 50-day and 200-day moving averages?
NVO is -7.44% from its 50-day SMA and -12.93% from its 200-day SMA based on the latest completed market-close snapshot from Oct 21, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is NVO's next earnings date?
NVO's next earnings date is currently listed as Nov 4, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does NVO pay a dividend?
NVO's dividend yield is 2.55% based on the latest completed market-close snapshot from Oct 21, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.